3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Carcinoma, Neuroendocrine
1
Carcinoid Tumor
1
Interventions
lutetium Lu 177 dotatate
11
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
pembrolizumab
4
cabozantinib
4
Nivolumab
3
Everolimus
3
lenvatinib
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Temozolomide
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
toripalimab
1
tislelizumab
1
telotristat ethyl
1
surufatinib
1
peposertib
1
pazopanib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
Surgical Procedures, Operative
1
Salts
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neuroendocrine Tumors
×
177Lu-octreotate
×
Clear all
NCT02754297
2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2
Active not recruiting
275 enrolled